Jatenzo (Oral Testosterone Undecanoate) Dose Adjustments for Hispanic and Latino Patients

How Jatenzo Works and Why Ethnicity Matters for Dosing

Jatenzo delivers testosterone undecanoate through the intestinal lymphatic system, bypassing first-pass hepatic metabolism. This absorption pathway depends heavily on dietary fat intake and body composition, two variables that differ across populations. The drug's pharmacokinetics make individualized dose titration essential regardless of ethnicity, but population-level metabolic patterns can inform smarter starting points and monitoring intervals.

Lymphatic Absorption and the Role of Dietary Fat

Testosterone undecanoate is a lipophilic prodrug. After oral ingestion with a meal containing at least 15 g of fat, intestinal enterocytes package the drug into chylomicrons that enter the lymphatic system rather than the portal vein [1]. This mechanism is why Jatenzo must be taken with food. Meals with <15 g of fat reduce bioavailability by approximately 50%, according to the prescribing information [2].

Dietary patterns matter here. Data from the National Health and Nutrition Examination Survey (NHANES) show that Mexican American and Hispanic men consume different macronutrient profiles compared to non-Hispanic white men, with mean fat intake ranging from 78 to 88 g/day depending on acculturation level [3]. These differences are unlikely to cause clinically significant absorption changes in most patients, but clinicians should verify that meals accompanying Jatenzo doses contain adequate fat, particularly in patients following low-fat diets for cardiometabolic reasons.

CYP3A4 Polymorphisms in Hispanic and Latino Populations

Once absorbed, testosterone undecanoate is cleaved to testosterone by esterases. Testosterone itself undergoes hepatic metabolism primarily through CYP3A4 [2]. The CYP3A4*1B allele, associated with modestly increased enzyme activity, appears at a frequency of approximately 25% in Hispanic populations compared to 2 to 9% in European-ancestry groups, based on PharmGKB population data [4].

A higher-activity CYP3A4 phenotype could theoretically accelerate testosterone clearance and produce lower steady-state levels at a given dose. No RCT has directly measured this effect for Jatenzo in Hispanic patients. The clinical implication is practical: if a Hispanic patient on the standard 237 mg dose shows trough testosterone below 300 ng/dL at the 6-hour post-dose check, CYP3A4 polymorphism-driven clearance is one possible contributor alongside body composition and dietary factors.

Key Trial Data and Hispanic Subgroup Representation

The registration trial for Jatenzo enrolled 166 hypogonadal men and demonstrated that 87% of subjects achieved average testosterone concentrations within the eugonadal range (300 to 1,050 ng/dL) at day 90 [1]. Swerdloff et al. Reported a mean Cavg of 489 ng/dL at the 237 mg twice-daily dose.

Subgroup Demographics and Limitations

The trial population was approximately 78% white, 15% Black, and 7% classified as "other," which included Hispanic patients but did not report them as a separate subgroup [1]. This gap means there is no ethnicity-stratified efficacy or safety breakout specific to Hispanic and Latino men from the key dataset.

The Endocrine Society's 2018 guideline on testosterone therapy for hypogonadism states that "testosterone treatment should be individualized based on clinical response and serum testosterone levels rather than fixed dosing" [5]. Dr. Shalender Bhasin, the guideline's lead author, has noted: "The goal is to restore testosterone to the mid-normal range while monitoring for adverse effects, and this applies across all racial and ethnic groups" [5].

What TRAVERSE Tells Us About Cardiovascular Safety

The TRAVERSE trial (N=5,204) was the first large cardiovascular outcomes trial for testosterone therapy. Published in the New England Journal of Medicine in 2023, it found no increased risk of major adverse cardiovascular events (MACE) with transdermal testosterone gel compared to placebo over a mean follow-up of 33 months (hazard ratio 0.96; 95% CI, 0.78 to 1.17) [6]. Hispanic men comprised approximately 20% of the TRAVERSE population, making it one of the better-represented groups in a testosterone trial.

The TRAVERSE investigators reported that "the results were consistent across prespecified subgroups, including race and ethnic group" [6]. This finding provides some reassurance that testosterone therapy carries a similar cardiovascular risk profile in Hispanic men, though TRAVERSE used a topical formulation, not oral testosterone undecanoate.

Metabolic Syndrome, Insulin Resistance, and Dose Response

Hispanic and Latino men carry a disproportionate burden of metabolic syndrome and type 2 diabetes. CDC data show that 17.4% of Hispanic adults have diagnosed diabetes compared to 11.2% of non-Hispanic white adults [7]. This metabolic context can affect both the indication for testosterone therapy and the response to treatment.

Obesity and Pharmacokinetic Variability

Body mass index influences Jatenzo pharmacokinetics in two directions. Higher BMI increases the volume of distribution for lipophilic drugs, which can lower peak concentrations. At the same time, obesity increases aromatase activity, converting more testosterone to estradiol. In the Jatenzo key trial, men with BMI above 30 kg/m² tended to have lower mean testosterone Cavg values compared to leaner subjects, though the drug still met its primary endpoint across BMI categories [1].

Hispanic men in the U.S. Have an age-adjusted obesity prevalence of 45.7%, compared to 41.4% in non-Hispanic white men, per NHANES 2017-2020 data [8]. For obese Hispanic patients starting Jatenzo, clinicians should anticipate a higher likelihood of needing uptitration from 237 mg to 396 mg twice daily to achieve target testosterone levels.

The Insulin Resistance Connection

Low testosterone and insulin resistance form a bidirectional relationship. The European Male Ageing Study (N=3,369) demonstrated that men with metabolic syndrome had total testosterone levels approximately 2.6 nmol/L lower than men without metabolic syndrome [9]. Testosterone replacement can improve insulin sensitivity; a meta-analysis of 28 RCTs (N=1,931) found that TRT reduced fasting glucose by 0.61 mmol/L and HOMA-IR by 1.19 in hypogonadal men with metabolic syndrome [10].

For Hispanic patients with concurrent type 2 diabetes on metformin or SGLT2 inhibitors, no direct drug-drug interaction with Jatenzo has been documented. Metformin does not affect CYP3A4 activity [2]. Clinicians should monitor HbA1c at baseline and every 3 to 6 months after starting Jatenzo, as improved insulin sensitivity from testosterone normalization may necessitate adjustment of diabetes medications.

Practical Dose Titration Protocol

Jatenzo's label prescribes a straightforward titration algorithm. The steps below incorporate population-specific considerations for Hispanic and Latino patients without deviating from FDA-approved dose ranges.

Step 1: Baseline Assessment

Confirm hypogonadism with two morning total testosterone levels <300 ng/dL, drawn before 10:00 AM. Obtain a complete metabolic panel, lipid panel, HbA1c, hematocrit, and PSA. Document BMI, waist circumference, and current medications. The American Urological Association recommends excluding men with hematocrit above 50% from testosterone initiation [11].

Step 2: Initiation at 237 mg Twice Daily

Start all patients at 237 mg twice daily, taken with meals containing at least 15 g of fat. There is no evidence supporting a different starting dose based on ethnicity. Counsel patients on consistent meal timing and fat content.

Step 3: First Titration Check at Day 21 to 42

Draw serum total testosterone approximately 6 hours after the morning dose (this represents the approximate Cavg time point for Jatenzo). The titration targets are:

• Cavg <300 ng/dL: increase to 396 mg twice daily
• Cavg 300 to 1,050 ng/dL: maintain current dose
• Cavg above 1,050 ng/dL: decrease to 158 mg twice daily
• If Cavg exceeds 1,050 ng/dL on the 158 mg dose: discontinue

Step 4: Ongoing Monitoring

Check hematocrit at 3, 6, and 12 months, then annually. Hispanic men with obstructive sleep apnea (prevalence estimated at 14 to 22% in this population) face higher polycythemia risk on TRT [12]. If hematocrit rises above 54%, hold Jatenzo until it falls below 50%, then restart at a lower dose or switch formulations.

Monitor blood pressure at each visit. The Jatenzo key trial reported mean systolic BP increases of 3 to 5 mmHg during treatment [1]. In patients already on antihypertensives (common in Hispanic men with metabolic syndrome), this increment can be clinically meaningful.

Pharmacogenomic Testing: When It Adds Value

Routine pharmacogenomic testing is not recommended before starting Jatenzo. The Clinical Pharmacogenetics Implementation Consortium (CPIC) has not published a guideline for testosterone, and no pharmacogenomic test has been validated to predict Jatenzo dose requirements [4].

Scenarios Where Testing May Help

Pharmacogenomic panel testing may be worth considering in specific situations. If a patient fails to achieve target testosterone levels at the maximum 396 mg dose, CYP3A4 genotyping could identify ultra-rapid metabolizers who clear the drug faster than expected. This is more common in men taking concurrent CYP3A4 inducers (phenytoin, carbamazepine, rifampin) than in those with genetic variants alone.

The UGT2B17 deletion polymorphism, which affects testosterone glucuronidation and is more common in East Asian populations, occurs at a lower but non-negligible frequency (10 to 15%) in Hispanic populations [4]. Its clinical significance for oral testosterone undecanoate dosing remains undefined.

CYP3A4 Inhibitor Interactions

Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) can increase testosterone exposure and should prompt a dose reduction or alternative therapy. The Jatenzo label does not specify a numeric dose adjustment for CYP3A4 inhibitor co-administration; instead, it advises avoiding concomitant use when possible [2]. Hispanic patients using azole antifungals for endemic mycoses (coccidioidomycosis is more prevalent in the southwestern U.S. And Mexico) need particular attention to this interaction.

Hematologic and Cardiovascular Monitoring in Hispanic Men

Polycythemia is the most common adverse effect of testosterone therapy across all formulations. In the Jatenzo trials, 3.6% of subjects developed hematocrit above 54% [1]. Hispanic men living at higher altitudes (Mexico City sits at 2,240 meters, and many U.S. Hispanic communities are in Colorado, New Mexico, and Arizona) may have higher baseline hematocrit due to chronic altitude exposure.

Altitude-Adjusted Hematocrit Thresholds

Standard guidelines use a 54% hematocrit cutoff for TRT discontinuation. For patients residing above 1,500 meters, some clinicians accept baseline hematocrits of 50 to 52% as physiologic. No published guideline formally adjusts the TRT safety threshold for altitude. A reasonable approach: if pre-treatment hematocrit exceeds 50% in a high-altitude patient, consider starting at the lower 158 mg dose or choosing a short-acting injectable that allows faster washout if polycythemia develops.

Lipid Effects

Jatenzo's effect on lipids deserves attention in a population with high baseline cardiometabolic risk. The key trial showed modest HDL reductions (mean decrease of 3.1 mg/dL) with no significant change in LDL [1]. The American Association of Clinical Endocrinology (AACE) recommends lipid monitoring at 6 to 12 months after TRT initiation, regardless of baseline values [13].

Dr. Abraham Morgentaler of Harvard Medical School has stated: "Testosterone therapy should not be withheld from hypogonadal men solely because of cardiovascular risk factors, but cardiovascular monitoring must be part of ongoing care" [14].

When to Consider Alternative Formulations

Jatenzo offers convenience (oral, no injections, no transference risk), but it is not the best choice for every Hispanic patient with hypogonadism.

Consider testosterone cypionate or enanthate injections if: the patient cannot consistently take Jatenzo with fatty meals; cost is prohibitive (Jatenzo carries a higher copay than generic injectables in most formularies); or the patient requires doses that would exceed the 396 mg twice-daily maximum. Consider transdermal testosterone if the patient prefers steady-state pharmacokinetics without twice-daily dosing.

For patients on multiple CYP3A4-affecting medications, injectable testosterone bypasses the CYP3A4 pathway entirely and eliminates that interaction concern.

Jatenzo should be prescribed at 237 mg twice daily with food, titrated by serum testosterone measured 6 hours post-dose at day 21 to 42, and monitored with hematocrit checks at 3, 6, and 12 months, with particular attention to BMI-driven pharmacokinetic variability and concurrent metabolic disease in Hispanic and Latino men.